COMPONENTS OF ANTITUMOR EXTRACT OF GRATIOLA OFFICINALIS LEAD TO TUMOR CELL DEATH BY APOPTOSIS DUE TO NEGATIVE REGULATION OF MCL-1 PROTEIN

Cardiometry Pub Date : 2023-11-01 DOI:10.18137/cardiometry.2023.29.conf.20

N. Polukonova, A.G. Demin, A. Polukonova

引用次数: 0

Abstract

Escape from cell death is one of the most prominent features of tumor cells and is closely related to the dysregulation of Bcl-2 family proteins. Among them, the anti-apoptotic protein Mcl-1 (myeloid cell leukaemia-1) acts as a master regulator of apoptosis in various human malignancies. The Mcl-1 -1 protein, whose main function is to protect tumor cells from apoptosis, is not the only product of the anti-apoptotic gene MCL1. On the contrary, another product of this gene, the shortened Mcl-1S protein, formed by alternative splicing, serves as a negative regulator of Mcl-1. Increased levels of Mcl-1S lead to inhibition of apoptosis-protective Mcl-1 and, consequently, tumor cell death by apoptosis (Senichkin, 2018). Mcl-1 inhibitors are currently being developed, which opens new perspectives to fight the hitherto untreatable addiction of cancer cells (Bolomsky et al., 2020).

查看原文本刊更多论文

红景天抗肿瘤提取物中的成分通过负调控 mcl-1 蛋白导致肿瘤细胞凋亡

逃避细胞死亡是肿瘤细胞最显著的特征之一，与 Bcl-2 家族蛋白的失调密切相关。其中，抗凋亡蛋白 Mcl-1（髓样细胞白血病-1）在各种人类恶性肿瘤中充当细胞凋亡的主调控因子。Mcl-1 -1 蛋白的主要功能是保护肿瘤细胞免于凋亡，但它并不是抗凋亡基因 MCL1 的唯一产物。相反，该基因的另一种产物，即通过替代剪接形成的缩短的 Mcl-1S 蛋白，是 Mcl-1 的负调控因子。Mcl-1S 水平的升高会抑制具有凋亡保护作用的 Mcl-1，从而导致肿瘤细胞凋亡（Senichkin，2018 年）。目前正在开发 Mcl-1 抑制剂，这为对抗迄今为止无法治疗的癌细胞瘾开辟了新的前景（Bolomsky 等人，2020 年）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiometry MEDICAL LABORATORY TECHNOLOGY-

自引率

0.00%

发文量

审稿时长

6 weeks

期刊介绍： Cardiometry is an open access biannual electronic journal founded in 2012. It refers to medicine, particularly to cardiology, as well as oncocardiology and allied science of biophysics and medical equipment engineering. We publish mainly high quality original articles, reports, case reports, reviews and lectures in the field of the theory of cardiovascular system functioning, principles of cardiometry, its diagnostic methods, cardiovascular system therapy from the aspect of cardiometry, system and particular approaches to maintaining health, engineering peculiarities in cardiometry developing. The interdisciplinary areas of the journal are: hemodynamics, biophysics, biochemistry, metrology. The target audience of our Journal covers healthcare providers including cardiologists and general practitioners, bioengineers, biophysics, medical equipment, especially cardiology diagnostics device, developers, educators, nurses, healthcare decision-makers, people with cardiovascular diseases, cardiology and engineering universities and schools, state and private clinics. Cardiometry is aimed to provide a wide forum for exchange of information and public discussion on above scientific issues for the mentioned experts.